Updating the approaches to define susceptibility and resistance to anti-tuberculosis agents

• Author(s): Antimycobacterial Susceptibility Testing Group ; Machado, D ; Viveiros, M
• Date: 2022
• Persistent ID: http://hdl.handle.net/10362/149035
• Origin: Repositório Institucional da UNL
• Subject(s): Antimycobacterial Susceptibility Testing; Breakpoints; Antimicrobial resistance; QR Microbiology; RM Therapeutics. Pharmacology; RA0421 Public health. Hygiene. Preventive Medicine; Pulmonary and Respiratory Medicine; Medical Laboratory Technology; Infectious Diseases; Microbiology (medical); Drug guides; SDG 3 - Good Health and Well-being; SDG 12 - Responsible Consumption and Production; SDG 17 - Partnerships for the Goals
• Document Type: Other
• Language: English
• Contributor(s): TB, HIV and opportunistic diseases and pathogens (THOP); Global Health and Tropical Medicine (GHTM); Instituto de Higiene e Medicina Tropical (IHMT); RUN

Description

Inappropriately high breakpoints have resulted in systematic false-susceptible AST results to anti-TB drugs. MIC, PK/PD and clinical outcome data should be combined when setting breakpoints to minimise the emergence and spread of antimicrobial resistance. https://bit.ly/3i43wb6